PharmaResources (Shanghai) Co. Ltd. A

PharmaResources (Shanghai) Co. Ltd. A

301230 · SHE · Healthcare / Biotechnology

31.45CNY-1.81 (-5.44%)

Price History

Full chart

Market Stats

Previous Close33.26
Open33.22
Day Range31.24 – 33.41
52-Week Range22.05 – 51.96
Volume16.27M
Market Cap6.98B
P/E (TTM)192.40
Forward P/E0.00
EPS0.20
Dividend Yield0.86%
Beta0.93
50-Day Avg32.07
200-Day Avg31.19

About

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule drugs. It is also involved in the research, development, and customized/commercial production of active pharmaceutical ingredients and key intermediates, including ticagrelor, oxiracetam, l-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2, as well as design, screening, and optimization of hit compounds and lead compounds; conducting of structural improvements; and provision of preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights. In addition, the company provides medicinal chemistry, process research and development, pharmaceutical research, molecular building blocks, and pharmacokinetics services. Further, it engages in pharmaceutical technology research and development activities. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ping Chen Ph.D.
  • Employees1.30K
  • HeadquartersBuilding 12, Shanghai, China, 201201, China
  • Websitehttps://www.pharmaresources.cn

Leadership

  • Dr. Ping Chen Ph.D.Co-Founder, GM & Chairman · b. 1958
  • Mr. Rongchang AnFounder & Director · b. 1965
  • Mr. Shicheng LiFinancial Manager & Accounting Supervisor · b. 1977
  • Mr. Weicai ZhenDeputy General Manager · b. 1962
  • Mr. Haifeng LiDeputy General Manager · b. 1975

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue282.99M448.21M478.88M489.72M544.47M688.35M
Growth (%)-+58.39%+6.84%+2.26%+11.18%+26.43%
Cost of Revenue162.53M274.81M302.30M338.51M414.54M499.63M
Gross Profit120.46M173.40M176.58M151.20M129.93M188.72M
Gross Margin42.57%38.69%36.87%30.88%23.86%27.42%
Operating Expense55.00M79.85M109.71M108.19M133.08M145.10M
Operating Income65.46M93.55M66.88M43.01M-3.15M43.62M
Operating Margin23.13%20.87%13.96%8.78%-0.58%6.34%
EBITDA--106.11M77.75M61.88M88.09M
EBITDA Margin--22.16%15.88%11.37%12.80%
Net Income48.69M73.58M67.18M37.62M17.08M34.29M
Net Income Margin17.21%16.42%14.03%7.68%3.14%4.98%
R&D11.83M17.14M32.65M37.34M47.26M37.15M
R&D as % of Total Revenue4.18%3.83%6.82%7.62%8.68%5.40%
Interest Expense1.22M2.53M4.79M5.46M9.28M8.29M
Interest Expense % of Total Revenue0.43%0.56%1.00%1.12%1.70%1.20%

Balance Sheet

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets373.99M557.81M1.30B1.49B1.32B1.31B
Total Liabilities110.81M209.37M188.38M369.62M283.73M309.87M
Total Equity263.18M348.44M1.11B1.12B1.03B1.00B
Cash111.28M108.44M763.64M204.30M84.52M59.11M

Cash Flow

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow54.45M105.12M99.29M20.86M80.86M135.51M
Capital Expenditure33.51M92.12M123.97M248.27M109.40M43.32M
Free Cash Flow20.94M13.01M-24.67M-227.41M-28.54M92.20M
Dividends Paid58.87M782.22K783.66K38.82M49.27M54.04M
FCF to OCF38.46%12.37%-24.85%-1090.26%-35.29%68.04%
Dividend Paid to FCF281.07%6.01%-3.18%-17.07%-172.65%58.62%

Earnings

Report DateDec 31, 2022Mar 31, 2023Aug 28, 2023Oct 25, 2023Dec 31, 2023Apr 25, 2024Aug 27, 2024Sep 30, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------
EPS Actual0.160.080.160.12-0.050.030.09-0.000.010.090.070.06-0.000.130.03
Surprise---------------
Timing--After-hoursPre-market-Pre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap6.98B
Enterprise Value7.11B
Trailing P/E192.40
Forward P/E0.00
Price / Sales9.95
Price / Book7.16
EPS0.20
Book Value5.65
Revenue (TTM)700.02M
Gross Profit (TTM)173.29M
EBITDA43.71M
Profit Margin5.47%
Operating Margin-1.88%
Return on Equity3.69%
Return on Assets0.68%
Shares Outstanding181.46M
Shares Float97.22M
Beta0.93
Dividend Yield0.86%
Dividend Rate0.33
Payout Ratio1.55%

Dividends

20262×
0.20Jul 16, 20260.08Jan 13, 2026
20252×
0.05Nov 14, 20250.25Jul 4, 2025
20242×
0.08Oct 24, 20240.25Jun 21, 2024
20231×
0.30Jun 21, 2023

Stock Splits

  • Jul 16, 20261.3:1
  • Jun 21, 20241.3:1
  • Jun 21, 20231.4:1